5 Free Dividend Stocks for 2022
Could these top payout stocks be part of the greatest wealth-creating tool in history?
Learn More.
Rafael Bejar, insider at Aptose Biosciences
Rafael Bejar Insider Alerts

Get notified the next time Rafael Bejar buys or sells Aptose Biosciences stock. Enter your email address below to get our daily insider buying and selling report.

Rafael Bejar Insider Information

Dr. Rafael Bejar is an internationally recognized physician scientist with extensive research and clinical experience in the area of hematologic malignancies. Dr. Bejar joined Aptose from UC San Diego where continues to serves as an Associate Professor of Clinical Medicine, cares for patients, and maintains a research laboratory focused on translational studies of myeloid malignancies. At UCSD, he founded the MDS Center of Excellence and led the Hematology Disease Team. There he has directed several clinical studies and served as an advisor for numerous companies including Celgene, Takeda, AbbVie, Astex, Genoptix, Forty Seven, PersImmune, and Daiichi-Sankyo. Outside UCSD, Dr. Bejar sits on the Scientific Advisory Board for the MDS Foundation, is a prior member of the National Comprehensive Cancer Network Guidelines Committee, and has led projects for the International Working Group for MDS. He is frequently invited to speak at national and international meetings and has published articles in a variety of journals including The New England Journal of Medicine, Journal of Clinical Oncology, Leukemia, Blood, and Blood Advances. Dr. Bejar has been board certified in Hematology and Oncology since completing his fellowship at the Dana-Farber Cancer Institute. He completed his internship in Internal Medicine at the University of Chicago followed by his residency at the Brigham and Women’s Hospital in Boston where he later served a Medical Chief Resident and an Instructor in Hematology. He holds an MD degree and Neuroscience PhD from UCSD and a BS in Physics from MIT.

What is Rafael Bejar's net worth?

The estimated net worth of Rafael Bejar is at least $12,400.00 as of November 19th, 2021. Dr. Bejar owns 10,000 shares of Aptose Biosciences stock worth more than $12,400 as of January 20th. This net worth evaluation does not reflect any other assets that Dr. Bejar may own. Learn More.

How do I contact Rafael Bejar?

The corporate mailing address for Dr. Bejar and other Aptose Biosciences executives is 251 CONSUMERS ROAD SUITE 1105, TORONTO A6, M2J 4R3. Aptose Biosciences can also be reached via phone at 858-926-2730 and via email at [email protected]

Has Rafael Bejar been buying or selling shares of Aptose Biosciences?

Rafael Bejar has not been actively trading shares of Aptose Biosciences within the last three months. Most recently, on Friday, November 19th, Rafael Bejar bought 10,000 shares of Aptose Biosciences stock. The stock was acquired at an average cost of $2.56 per share, with a total value of $25,600.00.

Who are Aptose Biosciences' active insiders?

Aptose Biosciences' insider roster includes Rafael Bejar (VP), William Rice (CEO), Warren Whitehead (Director), and Donald Wilson, Jr. (Major Shareholder).

Are insiders buying or selling shares of Aptose Biosciences?

In the last twelve months, Aptose Biosciences insiders bought shares 7 times. They purchased a total of 379,745 shares worth more than $567,509.81. In the last twelve months, insiders at the biotechnology company sold shares 2 times. They sold a total of 75,400 shares worth more than $208,790.00. The most recent insider tranaction occured on December, 20th when Director Denis R Burger bought 10,000 shares worth more than $14,500.00. Insiders at Aptose Biosciences own 8.4 % of the company.

Information on this page was last updated on 12/20/2021.

Rafael Bejar Insider Trading History at Aptose Biosciences

Transaction DateBuy/SellNumber of SharesAverage Share PriceTotal TransactionShares Held After TransactionDetails
11/19/2021Buy10,000$2.56$25,600.00View SEC Filing Icon  
See Full Table

Rafael Bejar Buying and Selling Activity at Aptose Biosciences

This chart shows Rafael Bejar's buying and selling at Aptose Biosciences by year and by quarter.

Skip ChartChart Data in Insider Trading History Table

Aptose Biosciences Company Overview

Aptose Biosciences logo
Aptose Biosciences Inc., a clinical-stage biotechnology company, discovers and develops personalized therapies addressing unmet medical needs in oncology in Canada. Its lead clinical program is APTO-253, which is a Phase I clinical trial for the treatment of patients with relapsed or refractory hematologic malignancies. The company has an agreement with CrystalGenomics, Inc. to research, develop, and commercialize CG026806, a non-covalent small molecule therapeutic agent, which is in preclinical stage for the treatment of acute myeloid leukemia and chronic lymphocytic leukemia/mantle cell lymphoma. The company was formerly known as Lorus Therapeutics Inc. and changed its name to Aptose Biosciences Inc. in August 2014. Aptose Biosciences Inc. was founded in 1986 and is headquartered in Mississauga, Canada.
Read More

Today's Range

Now: $1.24
Low: $1.22
High: $1.28

50 Day Range

MA: $1.77
Low: $1.11
High: $2.76

2 Week Range

Now: $1.24
Low: $1.08
High: $7.20

Volume

400,562 shs

Average Volume

506,408 shs

Market Capitalization

$114.35 million

P/E Ratio

N/A

Dividend Yield

N/A

Beta

1.51
[FREE Report] 5 Growth Stocks Under $49
Stay focused on the long-term with these 5 growth stock picks.
Learn More.